Increased demand for depot, depot-related drug distribution, and patient-centric services continues to inspire investment in infrastructure, pharmaceutical expertise and project management capability.
In 2017, the company expanded its market coverage from 148 to 155 countries countries, and added more than 120 new pharmaceutical, manufacturing, and clinical research clients.
Additionaly, Marken doubled the volume of work in its ten GMP-certified depots, tripled the volume of direct-to-patient (DTO) shipments, and expanded DTP into 50 countries.
The company also opened a new headquarters in Research Triangle Park, North Carolina and expanded its facility footprint to 47 locations.
Marken, a wholly owned subsidiary of UPS, is dedicated to the pharmaceutical and life sciences industries.
The company's more than 800 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 220 countries.
Additional services include biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients